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Summary 
Background 
High doses of intravenous methylprednisolone are recommended to treat relapses in patients 
with multiple sclerosis, but can be inconvenient and expensive. We aimed to assess whether 
oral administration of high-dose methylprednisolone was non-inferior to intravenous 
administration. 
Methods 
We did this multicentre, double-blind, randomised, controlled, non-inferiority trial at 13 
centres for multiple sclerosis in France. We enrolled patients aged 18–55 years with 
relapsing-remitting multiple sclerosis who reported a relapse within the previous 15 days that 
caused an increase of at least one point in one or more scores on the Kurtzke Functional 
System Scale. With use of a computer-generated randomisation list and in blocks of four, we 
randomly assigned (1:1) patients to either oral or intravenous methylprednisolone, 1000 mg, 
once a day for 3 days. Patients, treating physicians and nurses, and data and outcome 
assessors were all masked to treatment allocation, which was achieved with the use of saline 
solution and placebo capsules. The primary endpoint was the proportion of patients who had 
improved by day 28 (decrease of at least one point in most affected score on Kurtzke 
Functional System Scale), without need for retreatment with corticosteroids, in the per-
protocol population. The trial was powered to assess non-inferiority of oral compared with 
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intravenous methylprednisolone with a predetermined non-inferiority margin of 15%. This 
trial is registered with ClinicalTrials.gov, number NCT00984984. 
Findings 
Between Jan 29, 2008, and June 14, 2013, we screened 200 patients and enrolled 199. We 
randomly assigned 100 patients to oral methylprednisolone and 99 patients to intravenous 
methylprednisolone with a mean time from relapse onset to treatment of 7·0 days (SD 3·6) 
and 7·4 days (3·9), respectively. In the per-protocol population, 66 (81%) of 82 patients in the 
oral group and 72 (80%) of 90 patients in the intravenous group achieved the primary 
endpoint (absolute treatment difference 0·5%, 90% CI −9·5 to 10·4). Rates of adverse events 
were similar, but insomnia was more frequently reported in the oral group (77 [77%]) than in 
the intravenous group (63 [64%]). 
Interpretation 
Oral administration of high-dose methylprednisolone for 3 days was not inferior to 
intravenous administration for improvement of disability scores 1 month after treatment and 
had a similar safety profile. This finding could have implications for access to treatment, 
patient comfort, and cost, but indication should always be properly considered by clinicians. 
Funding 
French Health Ministry, Ligue Française contre la SEP, Teva. 
 
Introduction 
Multiple sclerosis is the neurological disease that most frequently causes disability in young 
adults. Multiple sclerosis is characterised by an inflammatory process that is initially focal or 
multifocal and associated with relapses, and which then becomes diffuse and chronic and is 
associated with a gradual worsening.1 Disease-modifying therapies have decreased the risk of 
accumulation of new focal lesions, but when relapses occur, high-dose intravenous 
corticosteroids, which have proven effectiveness in randomised controlled trials,2, 3, 4, 5, 6, 7, 
8 and 9 are commonly used. However, questions remain as to whether treatment could be given 
in a simpler and less invasive way (ie, orally). Little evidence has been shown for use of high-
dose oral steroids in multiple sclerosis.10 and 11 The authors of a Cochrane review12 did a meta-
analysis of five randomised trials from the past 20 years13, 14, 15, 16 and 17 including 215 patients 
that compared oral and intravenous steroids for the treatment of relapses. The authors 
concluded that the analysis did not show any significant differences in clinical, radiological, 
or pharmacological outcomes for oral or intravenous administration. However, they did point 
out major limitations, including methodological weaknesses and insufficient statistical power, 
underscoring the need for larger scale trials with sufficient power to compare the two 
regimens. Because infusions of corticosteroids are widely used to treat relapses of multiple 
sclerosis, it is important to clarify whether oral corticosteroids can be used with the same 
safety and efficacy. We therefore undertook the French Corticothérapie Orale dans les 
Poussées de Sclérose en Plaques (COPOUSEP) non-inferiority trial to assess the effect of oral 
versus intravenous administration of high-dose methylprednisolone, given soon after relapse 
onset, on recovery from multiple sclerosis relapses. 
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Research in context 
Evidence before this study 
On Sept 15, 2005, before this study, we searched PubMed using the following MeSH terms: 
“multiple sclerosis”, “relapses”, “corticosteroids”, “methylprednisolone”, “high-dose”, “oral”, 
“intravenous”, and “clinical trials”. We identified two randomised controlled trials (Alam and 
colleagues, 1993, and Barnes and colleagues, 1997) comparing efficacy, but not tolerability, 
of oral versus intravenous high-dose methylprednisolone, in 25 and 80 patients, respectively. 
When we did another search and review in December, 2014, we identified three additional 
randomised controlled studies showing no difference between oral and intravenous high-dose 
methylprednisolone on MRI and clinical parameters in 48 and 40 patients (Ramo-Tello and 
colleagues, 2014, and Martinelli and colleagues, 2009), and on pharmacokinetic parameters in 
16 patients (Morrow and colleagues, 2004). The data of these five randomised trials13, 14, 15, 
16 and 17 were included in a 2012 Cochrane review and meta-analysis by Burton and colleagues 
addressing the question of oral versus intravenous methylprednisolone, which found no 
difference in relapse recovery between oral and intravenous methylprednisolone, but also 
underlined insufficient power in these studies and several other limitations. 
Added value of this study 
Our study was the first adequately powered, randomised, double- blind, non-inferiority trial to 
compare a similar dosage of oral versus intravenous methylprednisolone, given early after 
onset of relapse of multiple sclerosis (1 week). We took into account the weaknesses of 
previous trials to design the study, using a methodology that corresponds to Burton and 
colleagues's recommendations in the Cochrane review, to resolve the question of oral 
corticosteroids to treat multiple sclerosis relapses. We showed oral methylprednisolone was 
non-inferior to intravenous administration in reduction of disability after relapses at 28 days. 
Implications of all the available evidence 
These results provide strong arguments for the possibility of improving management of 
multiple sclerosis relapses. Oral delivery is simpler and less invasive, more convenient for a 
quick primary and community care response, and allows obvious savings in cost and logistics. 
 
Methods 
Study design and participants 
In this multicentre, randomised, double-blind, non-inferiority trial, we enrolled patients at 13 
multiple sclerosis centres within hospitals in France. Eligible patients were aged 18–55 years 
with relapsing-remitting multiple sclerosis18 fulfilling the 2005 McDonald criteria19 and with 
an Expanded Disability Status Scale (EDSS) score of five or lower before the relapse that led 
to inclusion. Pre-relapse data were available in patients' files and the neurologist had to report 
it in the case report form at the screening visit. Because consensus is yet to be declared on the 
criteria for decisions about whether or not to treat relapses with corticosteroids, we defined 
the relapse of inclusion as follows: new or worsening neurological symptoms attributable to 
multiple sclerosis, lasting at least 24 h without pyrexia, responsible for an increase of at least 
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one point in one or more scores on the Kurtzke Functional System Scale (FSS20; congruent 
with potential subjective complaints), and resulting in a score of two or higher on the most 
affected scale (≥3 on the sensory scale). So we did not miss the window of opportunity for 
successful treatment with corticosteroids, the first dose of methylprednisolone had to be given 
no more than 15 days after onset of a relapse, which was preceded by a period of stability of 
at least 1 month. Disease-modifying therapy was permissible, except for natalizumab, 
mitoxantrone, and cyclophosphamide. Key exclusion criteria were medical disorders that 
could interfere with participation in the study (diabetes, infection that was not controlled with 
an appropriate antibiotic therapy, psychiatric disorder, or pregnancy). Further exclusion 
criteria are listed in the protocol (appendix). Each patient could only be included once in the 
trial. The study was done in accordance with the International Conference on Harmonisation 
Guidelines for Good Clinical Practice21 and the principles of the Declaration of Helsinki.22 
Local ethics committees approved the protocol. All patients provided written informed 
consent at enrolment. 
Randomisation and masking 
We allocated patients to the oral or intravenous group using a computer-generated 
randomisation list in a one to one ratio with blocks of four. The randomisation list was 
centralised by the pharmacist of the principal investigation centre (Rennes University 
Hospital), who assigned the next number available on the list to each newly enrolled patient 
and informed the local centre's pharmacist of the treatment group allocation. All treatment 
boxes contained three bags of sterile saline (0·9% NaCl), plus either three bottles of 
methylprednisolone 1000 mg and 30 placebo capsules for the intravenous group or 30 
capsules of methylprednisolone 100 mg for the oral group (so that all patients received an 
infusion and took ten capsules each day for 3 days). A nurse, separate from the one who gave 
the study drug, opened the box and prepared the infusion. Patients, treating neurologists, 
investigators assessing outcomes, nurses administering medication, and personnel analysing 
the data were masked to treatment allocation. Because both intravenous and oral 
methylprednisolone can induce a metallic taste that could prevent the masking of patients and 
treating clinicians or nurses to treatment assignment, the nurse administering the drugs made 
sure that patients swallowed capsules just as the infusion started, ensuring any taste would 
occur at the same time. 
Procedures 
The matching capsules of placebo and methylprednisolone 100 mg were manufactured at the 
pharmacy of Rennes University Hospital. Each batch was checked by the pharmacist against 
the specifications of the European Pharmacopoeia (uniformity of mass and uniformity of 
content, using UV spectrophotometry to verify the uniformity of content). 
Individual patients were assessed by the same treating neurologist throughout the study. The 
treating neurologist assessed the EDSS and FSS on day 1 just before the start of treatment; at 
days 3, 8, 28, and 180; and at any unscheduled visit when additional worsening before day 28 
or a fresh relapse after day 28 was suspected. An additional worsening before day 28 (by at 
least one point on one or more FSS scores) warranted treatment with the allocated study drug 
for a further 2 days (given in the same procedure). At each scheduled visit, the treating 
neurologist had to determine whether a patient's recovery was complete and, if so, to indicate 
the date. 
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To assess safety, patients completed self-report questionnaires 24 h, 48 h, 72 h, 8 days, and 28 
days after the start of treatment (available in appendix). They were asked to go through a list 
of symptoms commonly attributed to corticosteroid infusions and indicate which ones, if any, 
they experienced after being given the study treatment (metallic taste, hot flashes, headache, 
insomnia, agitation, anxiety, euphoria, gastric pain, nausea, vomiting, diarrhoea, palpitations, 
and chest pain). Additionally, up to the end of follow-up, treating neurologists reported any 
other unexpected or serious treatment-emergent adverse events, which were explored if 
necessary (physical examination, vital signs, and electrocardiograph; appendix). Patients with 
a history of digestive problems were given gastroprotective drugs and patients were given 
potassium supplementation if they had hypokalaemia or were on a concomitant treatment that 
could induce hypokalaemia. A specific drug (zolpidem 10 mg) for insomnia was 
systematically prescribed. 
Outcomes 
The primary endpoint was the proportion of patients in the per-protocol population who 
received 3 days of treatment (with no retreatment) who had improved by at least one point on 
the most affected FSS score by day 28. Secondary endpoints, measured over the 6 months 
after start of treatment of relapse that led to inclusion were a change in the overall EDSS 
score, the proportion of patients who improved by at least one EDSS point, the proportion of 
patients who recovered fully from the relapse, the time to total recovery, the proportion of 
relapse-free patients (no new relapse requiring corticosteroids), and the proportion of patients 
starting a disease-modifying therapy or switching to a different one. Quality of life was 
recorded and will be reported in a later report. These secondary outcomes included all patients 
in the per-protocol population, irrespective of whether they received retreatment with 
corticosteroids within 28 days. 
Statistical analysis 
The intention-to-treat and safety populations were defined as all randomly assigned patients 
who received at least one dose of any study medication. The study team monitored and 
classified protocol deviations, which were then validated by the data monitoring committee 
before database lock and before unblinding. The per-protocol population was composed of 
patients in the intention-to-treat population who had no major protocol deviations. 
Sample size was based on the primary efficacy endpoint in the per-protocol population who 
did not receive retreatment with corticosteroids. The predetermined non-inferiority margin δ 
was an absolute 15% difference (corresponding to a relative 18·75% difference) between 
treatment groups. Assuming a one-sided α of 0·05, a power of 80%, and an 80% proportion of 
patients improved at day 28 in the oral and intravenous groups (with no retreatment with 
methylprednisolone), 90 patients per group were needed. Assuming a 10% dropout rate, the 
required sample size was 200 patients. 
The non-inferiority margin of 15% was set only for the primary endpoint. Oral 
methylprednisolone efficacy was to be judged non-inferior to intravenous methylprednisolone 
when the lower limit of the 90% CI (computed using Dunnett and Gent's23 and 24 continuity 
corrected χ2 for non-inferiority) of the absolute difference between the proportions of patients 
improved at day 28 was higher than −δ=–15%. 
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We summarised baseline clinical and demographic characteristics with descriptive statistics. 
For secondary outcomes, we summarised with descriptive statistics and then compared 
between treatment groups using the χ2 test or Fisher's exact test (according to application 
conditions) for categorical variables, and the t test or Wilcoxon-Mann-Whitney test 
(according to application conditions) for continuous variables. We analysed time to total 
recovery with the Cox proportional hazards model, including treatment group as a factor, and 
provided the results as hazard ratios (HRs) with 95% CIs. We produced Kaplan-Meier plots 
for both time-to-event endpoints (time to first new relapse, time to total recovery). For 
participants who did not achieve the event, time to event was censored at the date of their last 
visit. 
We compared numbers of relapses per patient using Poisson regression including the 
treatment group and follow-up duration. All the analyses of the primary and secondary 
endpoints were done for both the intention-to-treat population and the per-protocol 
population. In an amendment to the protocol made by the data monitoring committee before 
database lock and before unblinding, patients whose day 8, 28, and 180 visits were delayed 
(taking place after day 12, 45, and 270, respectively) were excluded from the day 8, 28, and 
180 analyses. All patients with a recorded study end visit were deemed to have completed the 
study. 
Adverse events were summarised per treatment group, and analysed as proportions, in terms 
of patients with adverse events and overall number of adverse events, using the χ2 test for 
comparisons between the treatment groups. We also report presence of serious adverse events, 
their postulated correlation with treatment, and any resulting discontinuation. 
All the analyses were done using SAS statistical software (SAS version 9.3). An independent 
data monitoring committee at Rennes University Hospital reviewed study conduct and all 
safety data. This trial was registered with ClinicalTrials.gov, number NCT00984984. 
Role of the funding source 
The trial was designed independently of the sponsor and funders. Data were collected, 
analysed, and interpreted by the investigators, and the manuscript was edited and submitted 
totally independently of the sponsors and funders. SH had full access to data. ELP, DV, and 
GE were responsible for submission of the manuscript. 
Results 
Between Jan 29, 2008, and June 14, 2013, we enrolled 199 patients and randomly assigned 
100 to oral methylprednisolone and 99 to intravenous methylprednisolone (figure 1). 96 
(96%) patients assigned to the oral methylprednisolone group and 94 (95%) patients assigned 
to the intravenous methylprednisolone completed the study. 90 patients in the oral group and 
93 patients in the intravenous group were included in the per-protocol population (figure 1). 
Protocol deviations that excluded patients from the per-protocol population were unconfirmed 
multiple sclerosis (n=2), unconfirmed inclusion relapse (n=1), non-conformity of treatment 
(different dose, duration, or interruption from the protocol; n=6), non-conformity of 
retreatment (retreatment with corticosteroids not following the protocol treatment scheme; 
n=6), and non-conformity of follow-up (incomplete data; n=1; figure 1). 
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Figure 1.  
Trial profile 
All randomly assigned patients were included in the intention-to-treat population. 
Non-conformity of treatment and retreatment was defined as changes in dose, 
duration, interruption, or retreatment with corticosteroids not according to the protocol 
considerations. No patients with missing data for the primary endpoint at day 28 were 
retreated with additional methylprednisolone before day 28. MS=multiple sclerosis. 
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Demographic and baseline characteristics were similar in the treatment groups (table 1) and 
representative of a relapsing-remitting multiple sclerosis population not receiving second-line 
disease-modifying therapy (table 1). The data monitoring committee allowed the inclusion of 
two patients with a score of two for the sensory system. The inclusion relapse was most 
frequently pyramidal or sensory, and caused an increase in the mean EDSS score of 2·1 points 
(SD 1·2) in the oral group and 1·9 (1·1) points in the intravenous group as compared with 
before the relapse. The 1000 mg of methylprednisolone was given a mean of 7·0 (SD 3·6) 
days after relapse onset in the oral group and 7·4 (3·9) days after relapse onset in the 
intravenous group (table 1). Seven (9%) of 82 patients in the oral group and 12 (13%) of the 
90 patients were retreated for 2 additional days according to the protocol (p=0·31). 
Table 1.  
Demographic and baseline characteristics 
   Oral methylprednisolone group (n=100) 
Intravenous 
methylprednisolone group 
(n=99) 
Median age (years) 35·0 (18·2–62·6) 34·7 (18·3–58·7) 
Women 74 (74%) 74 (75%) 
Time from MS onset to randomisation 
 Median time (years) 6·2 (3·4–11·9) 5·7 (3·0–10·7) 
 0–2 years 18 (18%) 20 (20%) 
 2–5 years 19 (19%) 22 (22%) 
 >5 years 63 (63%) 56 (57%) 
Median residual EDSS 
score before inclusion 
relapse 
1·0 (0–2·0) 1·5 (1·0–2·0) 
Relapses in the previous year 
 Median number 0 (0–1) 0 (0–1) 
 0 60 (60%) 60 (61%) 
 1 29 (29%) 31 (31%) 
 2 7 (7%) 8 (8%) 
 ≥3 4 (4%) 0 
Baseline relapse 
 Median time from relapse onset (days) 6·5 (4·0–9·5) 7·0 (4·0–10·0) 
 Most affected functional system 
  Pyramidal 25 (25%) 33 (33%) 
  Sensory* 33 (33%) 26 (26%) 
  Cerebellar 10 (10%) 14 (14%) 
  Visual 13 (13%) 13 (13%) 
  Brainstem 19 (19%) 12 (12%) 
  Bowel and bladder 0 1 (1%) 
 Score of the most affected functional system 
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   Oral methylprednisolone group (n=100) 
Intravenous 
methylprednisolone group 
(n=99) 
  Pyramidal 3·0 (2·0–3·0) 3·0 (3·0–3·0) 
  Sensory* 3·0 (3·0–3·0) 3·0 (3·0–3·0) 
  Cerebellar 2·0 (2·0–3·0) 2·0 (2·0–2·0) 
  Visual 2·0 (2·0–4·0) 2·0 (2·0–3·0) 
  Brainstem 3·0 (2·0–3·0) 3·0 (2·0–3·0) 
EDSS score at inclusion 3·5 (3·0–4·0) 3·5 (3·0–4·0) 
Change in EDSS score due 
to relapse 2·0 (1·0–3·0) 2·0 (1·0–2·5) 
Disease-modifying therapy 
at inclusion 52 (52%) 55 (55%) 
 Interferon-beta 27 (27%) 31 (31%) 
 Glatiramer acetate 20 (20%) 21 (21%) 
 Mycophenolate mofetil 3 (3%) 1 (1%) 
 Azathioprine 1 (1%) 2 (2%) 
 Fingolimod 1 (1%) 0 
Data are median (range) or n (%), unless otherwise stated. MS=multiple sclerosis. 
EDSS=Expanded Disability Status Scale. 
*Two patients had a score of two on the sensory functional system (most affected 
system) but were included due to a decision from the data monitoring committee. 
  
At day 28, 66 (81%) of 82 patients who received oral methylprednisolone improved by at 
least one point on the most affected FSS score without need for retreatment with 
corticosteroids versus 72 (80%) of 90 who received intravenous methylprednisolone. The 
absolute treatment difference was 0·5% (90% CI −9·5 to 10·4). The lower limit of the 
confidence interval for the absolute difference (−9·5) was higher than the −15% margin 
specified in the protocol (figure 2, table 2). 
 
Figure 2.  
Treatment differences for day 28 improvement of at least one point in the most 
affected functional system scale score without need for retreatment 
Difference is oral versus intravenous methylprednisolone. 
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Oral 
methylprednisolone 
group 
Intravenous 
methylprednisolone 
group 
Absolute 
difference (90% 
CI non-inferiority)
Difference 
(95% CI) 
p 
value 
Day 28 
Number assessed 82 90 .. .. .. 
Patients improved by at least 1 point on the 
most affected functional system scale 
without retreatment with 
methylprednisolone 
66 (81%) 72 (80%) 0·5% (−9·5 to 10·4) .. .. 
Patients retreated for 2 days 7 (8%) 12 (13%) .. −5% (−19·7 to 10·1) 0·31 
Patients improved by at least 1 point on the 
most affected functional system 
(irrespective of retreatment) 
72 (88%) 84 (93%) .. 
−5·5% 
(−20·3 to 
9·5) 
0·21 
Patients improved by at least 1 EDSS point 
from baseline 63 (77%) 68 (76%) .. 
1·3% (−13·7 
to 16·2) 0·84 
Patients fully recovered from the relapse 32 (39%) 40 (44%) .. 
−5·4% 
(−20·2 to 
9·6) 
0·47 
Change in EDSS score from baseline −1·5 (1·0) −1·3 (0·9) .. −0·13 (−0·42 to 0·16) 0·57 
Change in the most affected functional 
system scale from baseline −1·7 (1·1) −1·6 (0·8) .. 
−0·05 (−0·34 
to 0·24) 0·79 
Day 180 (6 months) 
Number assessed 83 87 .. .. .. 
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Patients improved by at least 1 EDSS point 
from baseline 65 (78%) 68 (78%) .. 
0·2% (−14·9 
to 15·3) 0·98 
Patients fully recovered from the relapse* 59/90 (66%) 62/93 (67%) .. 
−1·1% 
(−15·6 to 
13·4) 
0·87 
Time to total recovery from the relapse 
(months)*† 1·8 (1·0–4·1) 1·3 (0·9–4·8) .. 
0·97 (0·66–
1·42)† .. 
Change in EDSS score from baseline −1·6 (1·0) −1·5 (1·1) .. −0·1 (−0·41 to 0·22) 0·69 
Change in the most affected functional 
system scale from baseline −2·1 (1·1) −2·0 (1·1) .. 
−0·2 (−0·49 
to 0·18) 0·30 
Number of relapses per patient, treated by 
methylprednisolone 0·4 (0·6) 0·3 (0·6) .. 
0·02 (−0·15 
to 0·19) 0·79 
Relapse-free patients* 63/90 (70%) 67/93 (72%) .. 
−2·0% 
(−16·6 to 
12·3) 
0·76 
Data are n (%), mean (SD), median (IQR), and n/N (%), unless otherwise stated. HR=hazard ratio. EDSS=Expanded Disability Status 
Scale. 
* 
Of those to complete trial. 
† 
HR (95% CI). 
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The proportion of patients whose score on the most affected FSS score improved by at least 
one point (irrespective of retreatment) was 72 (88%) of 82 in the oral group and 84 (93%) of 
90 in the intravenous group (p=0·21). At day 28, EDSS score had improved by at least one 
point relative to baseline in more than three quarters of patients in both groups (table 2). The 
mean EDSS score improved by 1·5 (SD 1·0) for the oral group versus 1·3 (0·9) for the 
intravenous group. By day 28, 32 (39%) patients in the oral group and 40 (44%) patients in 
the intravenous group had fully recovered from the relapse (p=0·47; table 2). Results for the 
intention-to-treat population were similar to those in the per-protocol population (appendix). 
Between day 28 and day 180, the mean number of new relapses in the per-protocol population 
that justified corticosteroids was 0·4 (SD 0·6) per patient in the oral group and 0·3 (0·6) per 
patient in the intravenous group and the proportion of patients free of relapse at this time was 
similar between groups (table 2). Results were similar in the intention-to-treat population 
(appendix). 
Over the total follow-up period, in the per-protocol population, 59 (66%) of 90 patients in the 
oral group and 62 (67%) of 93 patients in the intravenous group recovered fully from the 
relapse (table 2). The median time to total recovery was 1·8 months (IQR 1·0–4·1) in the oral 
group and 1·3 months (0·9–4·8) in the intravenous group (HR 0·97, 95% CI 0·66–1·42; 
figure 3). Both the proportion of patients whose EDSS score improved by at least one point 
and the mean improvement EDSS score were similar between groups in both the per-protocol 
and the intention-to-treat population (table 2, appendix). 
 
Figure 3.  
Kaplan-Meier curves for time to total recovery 
Kaplan-Meier estimates of time to total recovery in the per-protocol population. 
Dashes represent participants who did not achieve total recovery and were censored at 
the date of their last visit. 
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Because of the relapse leading up to inclusion in this trial, patients' therapeutic management 
could be modified during the study period. In the per-protocol population, 38 (42%) of 90 
patients in the oral group and 36 (39%) of 93 patients in the intravenous group started or 
switched disease-modifying therapy. In the oral group, 19 (50%) of the 38 patients started or 
moved to a first-line therapy (interferon-beta or glatiramer acetate), and the other 19 (50%) 
started or moved to a second-line therapy (nine to fingolimod, six to natalizumab, three to 
mitoxantrone, and one to mycophenolate mofetil). In the intravenous group, 22 (61%) of the 
36 patients started or moved to a first-line therapy, and the remaining 14 (39%) started or 
moved to a second-line therapy (five to fingolimod, four to natalizumab, four to mitoxantrone, 
and one to alemtuzumab). Findings were very similar in the intention-to-treat population (data 
not shown). 
The overall incidence of treatment-emergent adverse events reported by patients until day 28 
was similar in both groups, except for insomnia, which was reported by 77 (77%) of 100 
patients in the oral group and 63 (64%) of 99 patients in the intravenous group (p=0·0390; 
table 3). Two moderate-to-severe adverse events potentially related to methylprednisolone 
were reported in the oral group (one case of nausea and vomiting, and one of profound 
depression), and ten moderate-to-severe adverse events potentially related to 
methylprednisolone were reported in the intravenous group (three cases of abdominal pain, 
one of vomiting, five of insomnia, and one of profound depression; table 3). 
Table 3.  
Adverse events reported at least once by patients on self-questionnaires completed 
each day after 1000 mg of methylprednisolone and until day 28 
 
Oral 
methylprednisolone 
(n=100) 
Intravenous 
methylprednisolone (n=99) 
p 
value 
Patients with at least 
one adverse event 97 (97%) 97 (97%) .. 
Metallic taste 75 (75%) 80 (81%) 0·32 
Hot flashes 63 (63%) 58 (59%) 0·52 
Headache 72 (72%) 63 (64%) 0·21 
Insomnia 77 (77%) 63 (64%) 0·0390
Agitation 42 (42%) 29 (29%) 0·06 
Anxiety 39 (39%) 37 (37%) 0·81 
Euphoria 8 (8%) 11 (11%) 0·46 
Epigastric pain 43 (43%) 45 (45%) 0·73 
Nausea 32 (32%) 34 (34%) 0·73 
Vomiting 14 (14%) 12 (12%) 0·69 
Diarrhoea 23 (23%) 16 (16%) 0·22 
Palpitations 36 (36%) 29 (29%) 0·31 
Chest pain 18 (18%) 13 (13%) 0·34 
Rash 28 (28%) 30 (30%) 0·72 
Data are n (%), unless otherwise stated. Population is the intention-to-treat population. 
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Discussion 
In this trial, we show that oral administration of high-dose corticosteroids was non-inferior to 
intravenous corticosteroids in improvement of disability scores 28 days after a relapse. In the 
2012 Cochrane meta-analysis12 for oral versus intravenous methylprednisolone, the authors 
underlined the insufficient power of available studies and pointed out other important 
methodological limitations, such as a time from onset of relapse to first dose of up to 1 month, 
by which time the resolution phase has already spontaneously started.13 and 14 There was also 
little reliable concealment of allocation or randomisation method, a failure to use 
bioequivalent dosing (oral regimen ten times lower than the intravenous one in the largest 
study14), and little evidence that an appropriate assessment was done. Only one study16 used 
proper equivalence design techniques, but the patients and the clinical assessors of EDSS and 
adverse events were not masked to allocation. The authors concluded that none of the five 
trials showed a significant difference between the oral and intravenous administration of 
corticosteroids for the treatment of multiple sclerosis relapses, and recommended that future 
trials be done on a larger scale, and use an equivalence or non-inferiority design, as well as 
concealment of allocation, with definitive methods of randomisation, double blinding, and 
masking of interventions; clear and meaningful endpoints; and inclusion of relapses less than 
1 month after onset. We designed the methods of the trial in accordance with these 
recommendations. 
Because no consensus exists about which types of relapses justify corticosteroids, for the sake 
of rigour, we decided to focus on individual FSS scores rather than on the overall EDSS score 
(which can be stable even when a relapse has been confirmed18 and 25). To avoid mild relapses 
that might recover spontaneously, we established a criterion whereby the score on the 
functional system most affected by the exacerbation had to increase by at least one point, 
reaching a score of two or more, except for the sensory system, which had to reach a score of 
three or more (table 1). Our patients had significant relapses, mainly pyramidal or sensory, 
with the two relevant FSS scores reaching a median score of 3·0 (baseline) in both groups, 
and the EDSS increased by 2·0 points, reaching a median score of 3·5 (baseline) in the two 
groups. We used the same parameter to assess the primary outcome at 1 month, even though 
in the literature, the EDSS score is generally the primary outcome (either a variation from 
baseline or the percentage of patients whose score has improved by at least one point) that is 
compared between groups. In our study, the results did not vary much whether the measure 
was the most affected FSS score or the overall EDSS score. Patients with secondary 
progressive multiple sclerosis were not included to avoid confusion between the residual 
deficit from an exacerbation and underlying progressive disease. 
Similar to previous trials,15 we sought to assess the efficacy and safety of the 3 days of 
methylprednisolone 1000 mg that are commonly used for the treatment of multiple sclerosis 
relapses,26 even if some researchers maintain that corticosteroid treatment should last for 5 
days, rather than for 3 days.13, 16 and 27 As a result, patients could be treated for 2 extra days in 
the protocol, but were not included among those who reached the primary endpoint. However 
all the patients (treated for 3 days or 5 days) were included for secondary outcomes. 
We did not compare exactly bioequivalent doses of methylprednisolone for oral and 
intravenous administration because all patients received 1000 mg per day (as in some other 
trials13 and 16), even though bioavailability is estimated to be 82% when the drug is given orally 
versus intravenously17 and 28—hence why some researchers have designed trials with 1250 
mg15 or 1400 mg27 for oral doses and 1000 mg administered intravenously. We chose to use a 
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dose that is classically recommended for multiple sclerosis relapses in the oral group, 
reasoning that if the hypothesis of non-inferiority were satisfied, taking ten tablets of 
methylprednisolone 100 mg (marketed in France for other neurological indications) would be 
appropriate to manage multiple sclerosis relapses in real life. In our study, the oral 
administration of corticosteroids was not associated with more frequent new relapses over the 
subsequent 6 months (figure 2), despite the absence of tapering as recommended after the 
ONTT study.6, 7 and 8 
We enrolled patients no later than 15 days after relapse onset so that we did not miss the 
hypothetical window in which oral and intravenous steroid therapy might differ in efficacy, 
with quite a short median time to treatment start of 7 days in both groups. Our data gave some 
insight into the benefits of early administration of high doses of methylprednisolone (oral or 
intravenous) for treating relapses. 64% (128 of 199) of the intention-to-treat population was 
deemed to fully recover up to 6 months, meaning that 36% (71 of 199) had persistent residual 
signs confirmed by the treating physician. When Lublin and colleagues25 analysed patients 
from the placebo groups of two trials, 57% of the 140 patients having an EDSS increase 
during relapse had a residual deficit of at least 0·5 EDSS points for an average of 2 months 
after the relapse. However, the comparison should be cautious since the context of the study, 
the parameters analysed, and the period of assessment were different from ours. In our study, 
the median time to total recovery was 1·8 months in the oral group and 1·3 months in the 
intravenous group. This non-significantly quicker recovery in the intravenous group might be 
due to more patients (13% [12 of 90]) in the intravenous group being retreated with 
methylprednisolone before day 28 than in the oral group (8% [seven of 82]; figure 3). 
We based our study solely on clinical parameters, and could not add an MRI assessment. In 
daily practice, MRI is not used for the diagnosis of relapse, with diagnosis remaining based on 
clinical symptoms. Nor is it used to decide whether corticosteroids should be used. A 
limitation of the study might be the absence of MRI, but we note that the real benefit 
(shortening the duration of relapse) and the usefulness of intravenous high-dose 
methylprednisolone for relapses was mainly documented on clinical grounds.8 Furthermore, 
two randomised studies15 and 16 (involving 50 patients and 40 patients, respectively) that used 
MRI as a surrogate outcome reported no significant difference between intravenous and oral 
methylprednisolone groups on MRI findings at 1 month. 
In our study, the various specified adverse events were scored in self-questionnaires, which 
induces a greater incidence of adverse events than in spontaneous reporting. However, the 
tolerability was similar for both regimens, except for insomnia, which was more frequent in 
the oral group than in the intravenous group, even though patients could receive the 
corticosteroids at any time of day. This was also reported in the meta-analysis,12 and might be 
due to prolonged bioavailability. We therefore recommend giving the oral treatment in the 
morning. 
Our data support the use of oral methylprednisolone 1000 mg per day for 3 days to treat 
multiple sclerosis relapses. This finding could have implications for rapidity of access to 
treatment, patient comfort, and cost of the management of multiple sclerosis relapses. 
However, because oral administration is easier and cheaper, it might increase non-specialists' 
use of this treatment in a more liberal way, without thorough consideration of the indication. 
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